Pharmaceutical giant Merck announces the purchase of California-based biotech company Prometheus Biosciences for nearly $11 billion
The transaction diversifies Merck's portfolio and will help drive its"growth well into the next decade," Merck chairman and CEO Robert Davis stated.
Pharmaceutical giant Merck has announced the purchase of California-based biotech company Prometheus Biosciences for nearly $11 billion. The two companies "have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion," Merck said in a statement on Sunday.The company is developing a treatment for autoimmune diseases, including ulcerative colitis and Crohn's disease, dubbed PRA023.
"The agreement with Prometheus will accelerate our growing presence in immunology where there remains substantial unmet patient need," said Merck chairman and CEO Robert Davis, according to the statement.The transaction diversifies Merck's portfolio and will help drive its "growth well into the next decade," he added.
From September to December, sales at the company, known as MSD outside the United States and Canada, were $13.8 billion, up two percent year-on-year.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Merck to buy Prometheus Biosciences for about $11 billionMerck has agreed to acquire Prometheus Biosciences for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
Les mer »
Merck in talks to acquire Prometheus Biosciences: reportMerck is reportedly in talks to buy the San Diego-based Prometheus Biosciences in a promising deal that could be announced as early as Sunday.
Les mer »
Merck to buy Prometheus Biosciences for about $11 blnMerck & Co has agreed to acquire Prometheus Biosciences Inc for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
Les mer »
Merck in late-stage talks to acquire Prometheus Biosciences -WSJMerck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.
Les mer »
Merck to acquire Prometheus Biosciences for $10.8BMerck is acquiring San Diego-based Prometheus Biosciences in a $10.8 billion deal.
Les mer »
Merck to buy Prometheus Biosciences for $10.8 billionMerck & Co. Inc. announced Sunday a deal to acquire Prometheus Biosciences Inc. for $200 a share, or about $10.8 billion.
Les mer »